Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.
Andrew Kuykendall, MD
Advertisement
Andrew Kuykendall, MD, is an assistant member in the Department of Malignant Hematology at the Moffitt Cancer Center in Tampa, Florida.
Articles by Andrew Kuykendall, MD
Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.
Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5